Aquestive Therapeutics Inc (AQST) Implied Volatility Current

Tracking AQST implied volatility helps you identify when options premiums on Aquestive Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Aquestive Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when AQST IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Aquestive Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For AQST, tracking metrics like AQST IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on AQST signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where AQST implied volatility sits today versus where it has been. Our scanner ranks Aquestive Therapeutics Inc implied volatility against its historical range, surfaces extremes in AQST IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Aquestive Therapeutics Inc IV is rich or cheap — measure it, then act on it.